HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

BMS 641988

an antiandrogen and hormonal antineoplastic agent; structure in first source

Also Known As:

BMS-641988; BMS641988

Networked: 3 relevant articles (2 outcomes, 1 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Organic Chemicals: 133
- Imides: 79
  - BMS 641988: 3
Heterocyclic Compounds: 198
- Bridged-Ring Heterocyclic Compounds
  - Heterocyclic Bridged Bicyclo Compounds
    - BMS 641988: 3

Experts

1.	Balog, Aaron: 2 articles (08/2015 - 08/2009)
2.	Dell-John, Janet: 2 articles (08/2015 - 08/2009)
3.	Gottardis, Marco: 2 articles (08/2015 - 02/2011)
4.	Salvati, Mark E: 2 articles (08/2015 - 08/2009)
5.	Schweizer, Liang: 2 articles (08/2015 - 08/2009)
6.	Shan, Weifang: 2 articles (08/2015 - 08/2009)
7.	Attar, Ricardo: 1 article (08/2015)
8.	Cornelius, Georgia: 1 article (08/2015)
9.	DiMarco, John D: 1 article (08/2015)
10.	Fairfax, David: 1 article (08/2015)

Related Diseases

1.	Prostatic Neoplasms (Prostate Cancer) 08/15/2009 - "Overall, these data highlight that the unique preclinical profile of BMS-641988 may provide additional understanding for the hormonal treatment of prostate cancer." 02/15/2011 - "A first-in-man phase I study was conducted to define the safety and tolerability of oral BMS-641988 in patients with castration-resistant prostate cancer (CRPC). " 08/13/2015 - "BMS-641988 is efficacious in multiple human prostate cancer xenograft models, including CWR22-BMSLD1 where it displays superior efficacy relative to bicalutamide. " 08/13/2015 - "BMS-641988 (23) is a novel, nonsteroidal androgen receptor antagonist designed for the treatment of prostate cancer. " 08/13/2015 - "Discovery of BMS-641988, a Novel Androgen Receptor Antagonist for the Treatment of Prostate Cancer."
2.	Neoplasms (Cancer) 08/15/2009 - "Furthermore, BMS-641988 was efficacious in CWR-22-BMSLD1 tumors initially refractory to treatment with bicalutamide. " 08/15/2009 - "In the CWR-22-BMSLD1 human prostate cancer xenograft model, BMS-641988 showed increased efficacy over bicalutamide (average percent tumor growth inhibition >90% versus <50%), even at exposure levels of bicalutamide 3-fold greater than what can be attained in humans. "

Related Drugs and Biologics

1.	bicalutamide (Casodex)
2.	Androgen Antagonists (Antiandrogens)
3.	Androgen Receptor Antagonists
4.	Androgen Receptors (Androgen Receptor)

Related Therapies and Procedures

1.	Castration